These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

543 related articles for article (PubMed ID: 34630377)

  • 21. The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development.
    Alturki SO; Alturki SO; Connors J; Cusimano G; Kutzler MA; Izmirly AM; Haddad EK
    Front Immunol; 2020; 11():1880. PubMed ID: 32973779
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS.
    Rokni M; Ghasemi V; Tavakoli Z
    Rev Med Virol; 2020 May; 30(3):e2107. PubMed ID: 32267987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
    Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
    Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The immune response to SARS-CoV-2 and COVID-19 immunopathology - Current perspectives.
    Boechat JL; Chora I; Morais A; Delgado L
    Pulmonology; 2021; 27(5):423-437. PubMed ID: 33867315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progress and Challenges in the Development of COVID-19 Vaccines and Current Understanding of SARS-CoV-2- Specific Immune Responses.
    Kim KD; Hwang I; Ku KB; Lee S; Kim SJ; Kim C
    J Microbiol Biotechnol; 2020 Aug; 30(8):1109-1115. PubMed ID: 32627758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
    Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
    Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Severe COVID-19: what have we learned with the immunopathogenesis?
    Bordallo B; Bellas M; Cortez AF; Vieira M; Pinheiro M
    Adv Rheumatol; 2020 Sep; 60(1):50. PubMed ID: 32962761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?
    Sallenave JM; Guillot L
    Front Immunol; 2020; 11():1229. PubMed ID: 32574272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia.
    Lin L; Lu L; Cao W; Li T
    Emerg Microbes Infect; 2020 Dec; 9(1):727-732. PubMed ID: 32196410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lessons for COVID-19 Immunity from Other Coronavirus Infections.
    Sariol A; Perlman S
    Immunity; 2020 Aug; 53(2):248-263. PubMed ID: 32717182
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SARS-CoV-2: a new dimension to our understanding of coronaviruses.
    Araf Y; Faruqui NA; Anwar S; Hosen MJ
    Int Microbiol; 2021 Jan; 24(1):19-24. PubMed ID: 33231780
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A systematic review of SARS-CoV-2 vaccine candidates.
    Dong Y; Dai T; Wei Y; Zhang L; Zheng M; Zhou F
    Signal Transduct Target Ther; 2020 Oct; 5(1):237. PubMed ID: 33051445
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The SARS-Coronavirus Infection Cycle: A Survey of Viral Membrane Proteins, Their Functional Interactions and Pathogenesis.
    Wong NA; Saier MH
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33525632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19).
    Shanmugaraj B; Siriwattananon K; Wangkanont K; Phoolcharoen W
    Asian Pac J Allergy Immunol; 2020 Mar; 38(1):10-18. PubMed ID: 32134278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human Nasal and Lung Tissues Infected
    Alfi O; Yakirevitch A; Wald O; Wandel O; Izhar U; Oiknine-Djian E; Nevo Y; Elgavish S; Dagan E; Madgar O; Feinmesser G; Pikarsky E; Bronstein M; Vorontsov O; Jonas W; Ives J; Walter J; Zakay-Rones Z; Oberbaum M; Panet A; Wolf DG
    J Virol; 2021 Jun; 95(14):e0013021. PubMed ID: 33893170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interindividual immunogenic variants: Susceptibility to coronavirus, respiratory syncytial virus and influenza virus.
    Darbeheshti F; Mahdiannasser M; Uhal BD; Ogino S; Gupta S; Rezaei N
    Rev Med Virol; 2021 Nov; 31(6):e2234. PubMed ID: 33724604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coronaviruses: Is Sialic Acid a Gate to the Eye of Cytokine Storm? From the Entry to the Effects.
    Wielgat P; Rogowski K; Godlewska K; Car H
    Cells; 2020 Aug; 9(9):. PubMed ID: 32854433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Innate and adaptive immune responses to SARS-CoV-2 in humans: relevance to acquired immunity and vaccine responses.
    Jordan SC
    Clin Exp Immunol; 2021 Jun; 204(3):310-320. PubMed ID: 33534923
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences and similarities between innate immune evasion strategies of human coronaviruses.
    Hoenigsperger H; Sivarajan R; Sparrer KM
    Curr Opin Microbiol; 2024 Jun; 79():102466. PubMed ID: 38555743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.